Table 3.
BS: For patients with or at risk for familial breast cancer: Who do you think should undertake the following tasks?
| % | ||||
|---|---|---|---|---|
| Should be done by… | Myself | A genetic specialist | Other specialist | |
| (a) Explain the inheritance pattern of familial breast cancer | Francea | 49.4 (47.1) | 49.7 (46.4) | 0.9 (6.5) |
| Germany | 26.8 | 71.7 | 1.5 | |
| Netherlands | 66.4 | 32.8 | 0.8 | |
| UK | 30.7 | 66.7 | 2.6 | |
| p values: D-FChir, ≤.00011; D-FGyn, .00011; D-NL, ≤.0001; D-UK, ≤.004; FChir-NL, ≤.0001; FGyn-NL, ≤.003; FChir-UK, ≤.0001; FGyn-UK, ≤.0001; NL-UK, ≤.004 | ||||
| (b) Inform about breast cancer genetic risks for relatives | Francea | 54.2 (65.2) | 44.6 (26.8) | 1.2 (8.0) |
| Germany | 43.8 | 55.1 | 1.1 | |
| Netherlands | 56.8 | 43.2 | 0.0 | |
| UK | 23.2 | 74.8 | 2.0 | |
| p values: D-FChir, ≤.0001; D-FGyn, ≤.010; D-NL, ≤.0001; D-UK, ≤.0001; FChir-NL, ≤.0001; FGyn-NL, ≤.004; FChir-UK, ≤.0001; FGyn-UK, ≤.0001; NL-UK, ≤.0001 | ||||
| (c) Inform about breast cancer genetic testing | Francea | 56.8 (43.5) | 42.6 (50.7) | 0.6 (5.8) |
| Germany | 66.3 | 32.2 | 1.5 | |
| Netherlands | 40.3 | 59,7 | 0.0 | |
| UK | 20.2 | 77.8 | 2.0 | |
| p values: D-FChir, ≤.0001; D-FGyn, ≤.0001; D-NL, ≤.0001; D-UK, ≤.0001; FChir-NL, ≤.0001; FGyn-NL, ≤.010; FChir-UK, ≤.0001; FGyn-UK, ≤.0001; NL-UK, ≤.0001 | ||||
| (d) Disclose the breast cancer genetic test results to the patient | Francea | 9.7 (15.8) | 88.2 (79.2) | 2.1 (5.0) |
| Germany | 34.9 | 63.6 | 1.5 | |
| Netherlands | 4.2 | 94.1 | 1.7 | |
| UK | 3.3 | 94.1 | 2.6 | |
| p values: D-FChir, ≤.0001; D-FGyn, ≤.0001; D-NL, ≤.0001; D-UK, ≤.0001; FChir-NL, ≤.013; FGyn-NL, ≤.359; FChir-UK, ≤.002; FGyn-UK, ≤.088; NL-UK, ≤.460 | ||||
| (e) Provide support after breast cancer genetic testing | Francea | 73.0 (46.4) | 17.3 (24.3) | 9.7 (29.3) |
| Germany | 79.3 | 16.1 | 4.6 | |
| Netherlands | 48.7 | 47.1 | 4.2 | |
| UK | 29.6 | 61.8 | 8.6 | |
| p values: D-FChir, ≤.0001; D-FGyn, ≤.004; D-NL, ≤.0001; D-UK, ≤.0001; FChir-NL, ≤.0001; FGyn-NL, ≤.0001; FChir-UK, ≤.0001; FGyn-UK, ≤.0001; NL-UK, ≤.0001 | ||||
| (f) Inform about possible manage- ment options available after the results of breast cancer genetic testing | Francea | 63.5 (50.3) | 33.2 (36.2) | 3.3 (13.5) |
| Germany | 79.3 | 17.2 | 3,5 | |
| Netherlands | 74.8 | 23.5 | 1.7 | |
| UK | 62.1 | 35.3 | 2.6 | |
| p values: D-FChir, ≤.0001; D-FGyn, ≤.0001; D-NL, ≤000; D-UK, ≤.0001; FChir-NL, ≤.0001; FGyn-NL, ≤.065; FChir-UK, ≤.0001; FGyn-UK, ≤.0001; NL-UK, ≤.0001 | ||||
Sample size: France subgroups: FGyn, n = 333, FChir, n = 145; Germany, n = 466; Netherlands, n = 144; UK, n = 123
aFrance subgroup FGyn presented in brackets